Quantcast

Novartis’ clinical trial of inhaled dual combination QMF149 for patients with asthma, meets primary endpoint

Novartis Phase III Palladium clinical trial has met the primary endpoing, as it showed that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate (IND/MF) in development, was superior to mometasone furoate (MF) at medium and high doses in improving lung function.

Read more

Anavex Life Sciences Presents ANAVEX trials on Alzheimer’s-

Anavex Life Scienceshas announced late breaking oral communication at CTAD 2019, by presenting the interim 2-Year (104)-Week) data from the Phase 2a ANAVEX®2-73 (blarcamesine) extension study, with Alzheimer’s disease patients followed for up to five years, at the 12th Clinical Trials On Alzheimer’s Disease (CTAD) 2019 Conference in San Diego, CA (December 4-7, 2019).

Read more

ViGeneron closes Series A round which attracts WuXi AppTec and Sequoia Capital China

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.

Read more